Denver, Colorado -
Cellectar Biosciences: Oversubscribed $140M Raise Signals High-Stakes Oncology Push
Cellectar Biosciences (NASDAQ:CLRB) is stepping into a pivotal phase with an oversubscribed financing package of up to $140 millionclear evidence that institutional capital is aggressively backing its late-stage oncology pipeline. The deal, led by Nantahala Capital, combines $35 million upfront with up to $105 million in milestone-based funding, positioning the company to advance its lead candidate, iopofosine I 131, toward accelerated FDA approval in Waldenström macroglobulinemia (WM).
The timing aligns with compelling clinical momentum. Updated Phase 2b CLOVER WaM data demonstrated an 83.6% overall response rate and durable efficacy in heavily pretreated patients, the kind of dataset regulators look for in accelerated pathways. With a confirmatory trial planned for late 2026 and NDA strategy underway, Cellectar is transitioning from development-stage risk to potential commercialization inflection.
NeOnc Technologies: Insider Buying Blitz Ahead of Brain Cancer Catalysts
NeOnc Technologies (NASDAQ:NTHI) is drawing attention as CEO Amir Heshmatpour ramps up insider buying, committing over $500,000 in recent weeks and nearly $1 million over the past year. In biotech, insider conviction at this scale often precedes major catalysts and NeOnc has several on deck.
The company’s NEO100 Phase 2a trial in recurrent high-grade glioma is fully enrolled, with interim data expected soon. Combined with completed Phase 1 work on NEO212, NeOnc is advancing a platform designed to overcome the blood-brain barrier, a long-standing obstacle in CNS oncology. With regulatory alignment discussions underway, the next data release could materially reshape the company’s trajectory.
Backblaze: AI Data Boom Fuels Cloud Storage Acceleration
Backblaze (NASDAQ:BLZE) is capitalizing on the exploding demand for AI data infrastructure, posting 24% growth in its B2 cloud storage segment and 12% overall revenue growth in Q1 2026. The company is increasingly positioning itself as a cost-efficient alternative in the AI storage arms race.
Notably, AI customer count surged 76% year-over-year, with new wins contributing meaningful contract value. As AI models shift toward multimodal data, storage demand is scaling exponentially and Backblaze is leaning into that trend with pricing adjustments and ecosystem expansion. Improved margins and a swing to non-GAAP profitability suggest the company is beginning to translate growth into operational leverage.
Digi Power X: $1.1B AI Infrastructure Deal Marks Arrival in Big Leagues
Digi Power X (NASDAQ:DGXX) has landed a transformative 10-year, $1.1 billion AI colocation agreement with Cerebras Systems, with potential upside reaching $2.5 billion. The deal centers on a 40 MW AI-optimized data center campus in Alabama, purpose-built for next-generation compute workloads.
With construction already underway and Phase 1 expected online by December 2026, Digi Power X is securing long-term revenue visibility while anchoring itself in the rapidly expanding AI infrastructure stack. Ownership of the underlying real estate and pre-secured power agreements significantly reduce execution risk, making this one of the more compelling infrastructure plays tied to AI growth.
Viridian Therapeutics: Dual Phase 3 Wins Position TED Franchise for Breakout
Viridian Therapeutics (NASDAQ:VRDN) is emerging as a dominant force in thyroid eye disease (TED), delivering positive Phase 3 results for elegrobart in both active and chronic settings. In the REVEAL-2 trial, the drug achieved up to 54% proptosis response rates versus just 15% for placebo, highly statistically significant outcomes that reinforce its clinical potential.
With a Biologics License Application (BLA) planned for Q1 2027 and a near-term FDA decision on veligrotug (PDUFA June 30, 2026), Viridian is on the cusp of becoming a commercial-stage company. Its strategy, pairing IV and subcutaneous therapies, could redefine treatment convenience and expand the addressable market. Backed by a strong $762 million cash position, the company appears well-funded for launch execution.
Cytokinetics: First-in-Class Success in Untreated Heart Condition
Cytokinetics (NASDAQ:CYTK) delivered a major clinical milestone with positive Phase 3 results for aficamten in non-obstructive hypertrophic cardiomyopathy (HCM), a condition with no approved therapies targeting its underlying cause.
The ACACIA-HCM trial met dual primary endpoints, showing statistically significant improvements in both symptom burden and exercise capacity. These results not only validate aficamten’s mechanism but also open the door to a potentially first-in-class treatment opportunity. With regulatory discussions ahead, Cytokinetics could be entering a high-value commercialization pathway in a largely untapped market.